The U.S. Agency for International Development (USAID) submits this report pursuant to Section 7019(e) of Division F of Public Law (P.L.) 116-6, the Department of State, Foreign Operations, and Related Programs Appropriations Act, 2019, which incorporates by reference the requirements of Senate Report 115-282:

The Committee recognizes that Multidrug-Resistant Tuberculosis (MDR–TB) is a national security threat. Not later than 180 days after enactment of the act, the USAID Administrator shall submit a report to the Committee on implementation of Goals 2 and 3 of the National Action Plan for Combating Multidrug-Resistant Tuberculosis, issued on December 22, 2015, including a description of: (1) efforts to increase case discovery; (2) the approximate number of people receiving treatment for MDR–TB; and (3) an estimate of the resources required to achieve stated objectives.

4 results

Combating Multidrug-Resistant Tuberculosis: Year Five Report Of The National Action Plan

Despite being preventable and curable, tuberculosis (TB) is one of the leading infectious disease killers, alongside COVID-19. In 2020, COVID-19 and associated measures to control it severely disrupted TB diagnosis and care services in the world’s highest TB burden countries, threatening to reverse years of progress.

Combating Multidrug-Resistant Tuberculosis: Year Four Report Of The National Action Plan

Tuberculosis (TB) remains the world’s deadliest infectious disease. In 2019, an estimated ten million (estimated range, 8.9–11.0 million) people developed this severely debilitating disease, and 1.4 million (estimated range, 1.3–1.5 million) died as a result.1 TB is caused by Mycobacterium tuberculosis (Mtb), a bacterium that may be transmitted through the air from person to person.

Combating Multidrug-Resistant Tuberculosis: Year Three Of The National Action Plan Report

This report outlines how the Federal Departments and Agencies have successfully met the global target and all of the milestones for Year Three.